Allogene Therapeutics Seeks Shareholder Approval to Double Authorized Shares After Highly Dilutive $200M Offering

summarizeSummary

Allogene Therapeutics is asking shareholders to approve doubling its authorized common stock to 800 million shares, which would enable significant future dilution, following a recent $200 million public offering that diluted existing shareholders by approximately 29%.

check_boxKey Events · Financing and Capital Events · ALLO

• Shareholders to Vote on Doubling Authorized Shares

  The company is seeking approval to increase authorized common stock from 400 million to 800 million shares. If all additional shares were issued, it would represent a potential dilution of approximately 116% relative to current outstanding shares.

• Executive Option Exercises Tied to Approval

  Section 16 officers and the Executive Chair have agreed not to exercise 23.4 million outstanding stock options unless the authorized shares amendment is approved, directly linking the proposal to executive compensation.

• Recent Highly Dilutive Public Offering Completed

  On April 16, 2026, Allogene Therapeutics completed a public offering, selling 100.2 million shares at $2.00 per share, raising $200.4 million. This offering resulted in approximately 29% dilution to shareholders based on shares outstanding prior to the offering.

• Board Size Reduction and Director Departure

  Director Todd Sisitsky was not nominated for re-election, leading to a reduction in the Board of Directors' size from 11 to 10 members, effective after the annual meeting.

auto_awesomeAnalysis · ALLO · Life Sciences

Allogene Therapeutics has filed its definitive proxy statement for its annual meeting, seeking shareholder approval to increase its authorized common stock from 400 million to 800 million shares. This proposal, if approved, would create headroom for an additional 400 million shares, representing a potential dilution of approximately 116% relative to the current outstanding shares. The company explicitly states that its Section 16 officers and Executive Chair have agreed not to exercise 23.4 million outstanding stock options unless this amendment is approved, directly linking the proposal to significant executive compensation. This filing also discloses a recently completed public offering on April 16, 2026, where the company sold 100.2 million shares at $2.00 each, raising $200.4 million. This offering alone resulted in approximately 29% dilution based on shares outstanding prior to the offering. An affiliate of director Todd Sisitsky purchased shares in this offering at a slight discount to the public price. The combination of a recently completed, highly dilutive offering and the request for authorization of further massive potential dilution makes this a critical event for existing shareholders.